Floatz logo

Cypate-Cyclo(Cys-Gly-Arg-Asp-Ser-Pro-Cys)-Lys-OH (LS301)

Invasive Duct Carcinoma of Breast

Integro Theranosticsprotein_peptidePhase 1/2Active
CCC
51/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
36/ 100
Competitive Position
95/ 100

Competitive context

9 Active assets in the Invasive Duct Carcinoma of Breast cohort.

Asset / SponsorPhaseRating
Carboplatin
GBG Forschungs GmbH
Phase 3BBB
Letrozole
University of Washington
Phase 4BBB
Cyclophosphamide
UMC Utrecht
Phase 3BB
IMMUNOGLOBULIN G1, ANTI-(HUMAN NEU (RECEPTOR)) (HUMAN-MOUSE MONOCLONAL 2C4 HEAVY CHAIN), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL 2C4 .KAPPA.-CHAIN, DIMER
GBG Forschungs GmbH
Phase 3BB
CIS-DIAMMINEDICHLOROPLATINUM II
RenJi Hospital
Phase 3BB

View all 35 →

Same molecule, other indications

Cypate-Cyclo(Cys-Gly-Arg-Asp-Ser-Pro-Cys)-Lys-OH (LS301) is also rated in:

non-small cell lung carcinomaDormant
CCC
Indicative ·
52 / 100
View asset →
ductal breast carcinoma in situDormant
CCC
Indicative ·
51 / 100
View asset →
gastrointestinal stromal tumorDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →